Ravinder Bhalla, MD
Child & Adolescent Psychiatry · Ridgewood, NJNPI 1841214566
Payments from drug & device makers
Across 884 payments — averaging $141.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$88K
- AbbVie$15K
- Alkermes, Inc.$12K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- plus $4K from 20 others
What the payments were for
- Consulting fees$6,5005%
- Speaking & faculty fees$100,82581%
- Travel & lodging$1,7411%
- Food & beverage$15,63513%
- Education$3310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 190 | $88,445 |
| AbbVie(2 entities) | 109 | $14,629 |
| Alkermes, Inc. | 124 | $11,598 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $3,504 |
| Otsuka America Pharmaceutical, Inc. | 73 | $1,267 |
| Lundbeck LLC | 88 | $1,229 |
| Neurocrine Biosciences, Inc. | 67 | $1,124 |
| Johnson & Johnson | 47 | $699 |
| Supernus Pharmaceuticals, Inc. | 42 | $676 |
| Sunovion Pharmaceuticals Inc. | 37 | $496 |
| Vanda Pharmaceuticals Inc. | 19 | $375 |
| Boston Scientific | 2 | $145 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Gilead | 1 | $108 |
| Ironshore Pharmaceuticals Inc. | 7 | $104 |
| Merck | 1 | $90 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $57 |
| Indivior Inc. | 3 | $46 |
| Avanir Pharmaceuticals, Inc. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Tris Pharma Inc | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$125,032 in reported general payments places this provider in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.
See all child & adolescent psychiatry providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 15 | $111,550 |
| IngrezzaValbenazine Tosylate | 11 | $86,655 |
| AristadaAripiprazole Lauroxil | 21 | $69,837 |
| Abilify MaintenaAripiprazole | 13 | $38,404 |
| FanaptIloperidone | 13 | $26,779 |
| Invega SustennaPaliperidone Palmitate | 13 | $22,791 |
| Lurasidone Hcl | 25 | $15,745 |
| Divalproex Sodium ErDivalproex Sodium | 80 | $2,122 |
| Quetiapine Fumarate | 81 | $1,339 |
| Lamotrigine | 61 | $648 |
| Aripiprazole | 27 | $567 |
| Doxepin Hcl | 47 | $417 |
| Risperidone | 47 | $417 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 17 | $411 |
| Buspirone Hcl | 12 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $88,445 | $111,55015 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,124 | $86,65511 claims |
| Alkermes, Inc.Aristada | $11,598 | $69,83721 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,267 | $38,40413 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $375 | $26,77913 claims |
| Johnson & JohnsonInvega Sustenna | $699 | $22,79113 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $8029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.
Other child & adolescent psychiatry in Ridgewood
- Watutantri DealwisRidgewood$4K
- David KrefetzClementon$122K
- Tahir KhwajaNorth Brunswick$59K
- Steven DyckmanEast Brunswick$53K
- Eric BartkyLivingston$51K
- Bohdan CzartoryskyParsippany$21K
- Akhtar HossainSomerville$19K
- Suzanne LindNew Brunswick$18K
- Aykut OzdenEdgewater$17K
- Valeria KorshunovaHackensack$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.